Cytek Biosciences (CTKB) Receives a Buy from Piper Sandler

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Cytek Biosciences (CTKB – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $6.27.

Westenberg covers the Healthcare sector, focusing on stocks such as Zoetis, Exact Sciences, and Myriad Genetics. According to TipRanks, Westenberg has an average return of -2.1% and a 39.38% success rate on recommended stocks.

Currently, the analyst consensus on Cytek Biosciences is a Strong Buy with an average price target of $10.25.

CTKB market cap is currently $823M and has a P/E ratio of -71.41.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cytek Biosciences (CTKB) Company Description:

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.